title: Novel targets in head and neck cancer: should we be optimistic?
abstract: Head and neck squamous cell carcinomas have distinct mutation and copy-number profiles depending on human papillomavirus status. Although several challenges remain in biomarker implementation and clinical trial feasibility, incorporating available genomic data will expedite the development of novel therapeutics and predictive biomarker-driven clinical trials. See related article by Seiwert et al., p. 632.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Gabriel S
authors.initials: GS
authors.lastname: Krigsfeld
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. cchung11@jhmi.edu.
authors.forename: Christine H
authors.initials: CH
authors.lastname: Chung
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000209:etiology*; D005260:Female; D023281:Genomics; D006258:Head and Neck Neoplasms / Q000209:etiology*; D006801:Humans; D008297:Male; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications*; D014412:Tumor Virus Infections / Q000150:complications*